FUKOKU MUTUAL LIFE INSURANCE Co Sells 180 Shares of Johnson & Johnson (NYSE:JNJ)

FUKOKU MUTUAL LIFE INSURANCE Co reduced its position in Johnson & Johnson (NYSE:JNJGet Rating) by 1.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,480 shares of the company’s stock after selling 180 shares during the period. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Johnson & Johnson were worth $2,202,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Lee Financial Co grew its holdings in Johnson & Johnson by 8.3% in the third quarter. Lee Financial Co now owns 2,765 shares of the company’s stock worth $451,000 after purchasing an additional 211 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in Johnson & Johnson by 3.9% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 50,207 shares of the company’s stock worth $8,202,000 after buying an additional 1,867 shares during the last quarter. Toews Corp ADV increased its position in Johnson & Johnson by 2.9% during the 3rd quarter. Toews Corp ADV now owns 7,200 shares of the company’s stock valued at $1,176,000 after buying an additional 200 shares in the last quarter. Sheets Smith Wealth Management raised its stake in Johnson & Johnson by 2.4% in the third quarter. Sheets Smith Wealth Management now owns 13,362 shares of the company’s stock valued at $2,183,000 after buying an additional 308 shares during the last quarter. Finally, Kestra Advisory Services LLC grew its stake in shares of Johnson & Johnson by 4.3% during the third quarter. Kestra Advisory Services LLC now owns 326,858 shares of the company’s stock worth $53,395,000 after acquiring an additional 13,562 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, VP Thibaut Mongon sold 35,246 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 16,410 shares of the firm’s stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total value of $2,845,822.20. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at $12,366,753.62. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JNJ. Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They set a “strong-buy” rating for the company. Barclays started coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price on the stock. Raymond James dropped their price target on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Finally, Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE:JNJ opened at $168.31 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $155.72 and a 12-month high of $186.69. The business has a 50 day moving average of $176.07 and a two-hundred day moving average of $171.13. The company has a market capitalization of $440.04 billion, a PE ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.